Combined radiation and immune checkpoint inhibitor therapy for metastatic or recurrent hepatocellular carcinoma: a real-world study of 108 patients

QR Code

Combined radiation and immune checkpoint inhibitor therapy for metastatic or recurrent hepatocellular carcinoma: a real-world study of 108 patients

BackgroundThe prognosis of metastatic or recurrent hepatocellular carcinoma (HCC) remains poor, and new treatment strategies are warranted. Despite promising preclinical results demonstrating that radiation primes the immune system and produces a synergistic antitumor response for long-term disease...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yirui Zhai, Yefan Zhang, Fan Wu, Jianguo Zhou, Lingxia Xin, Feng Ye, Wei Sun, Huiying Zeng, Yan Song, Yongkun Sun, Wen Zhang, Shu-Lian Wang, Yuan Tang, Hui Fang, Pan Zhao, Yueping Liu, Ningning Lu, Shunan Qi, Hao Jing, Wenwen Zhang, Yongwen Song, Ye-Xiong Li, Liming Wang, Bo Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-08-01
Series:	Frontiers in Immunology
Subjects:	hepatocellular carcinoma radiotherapy immunotherapy immune checkpoint inhibitor PD-1/PD-L1 inhibitor
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1594577/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Case Report: Tislelizumab-induced insulin-dependent diabetes mellitus: a case report and literature review
by: Panpan Ji, et al.
Published: (2025-07-01)

Immune Checkpoint Inhibitor‐Based Therapy as the First‐Line Treatment for Advanced Non‐Small Cell Lung Cancer: Efficacy, Challenges, and Future Perspectives
by: Xingxiang Pu, et al.
Published: (2025-06-01)

Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors
by: Wenke Li, et al.
Published: (2025-07-01)

Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
by: Sho Yoshimoto, et al.
Published: (2023-12-01)

Monitoring Pseudoprogression Using Circulating Small Extracellular Vesicles Expressing PD‐L1 in a Melanoma Patient Treated With Immune Checkpoint Inhibitors
by: Charlée Nardin, et al.
Published: (2025-06-01)

Cancer therapeutic implications of microRNAs in the regulation of immune checkpoint blockade
by: Yan Zhang, et al.
Published: (2019-08-01)

PREDICTIVE RESPONSE MARKERS FOR IMMUNE RESPONSE BLOCKS
by: G. A. Janus, et al.
Published: (2020-09-01)

Immune Checkpoint Inhibitors in Melanoma Treatment: Advances and Obstacles
by: A. V. Sultanbaev
Published: (2025-04-01)

PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma
by: Jitong Zhou, et al.
Published: (2025-07-01)

Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents
by: E. V. Shubnikova, et al.
Published: (2020-03-01)

Immune checkpoint changes correlate with the progression and prognosis of amyotrophic lateral sclerosis
by: Sheng Chen, et al.
Published: (2025-12-01)

Phase 3 Trials of Neoadjuvant, Perioperative, and Adjuvant Chemoimmunotherapy for Resectable, Early-Stage NSCLC: Comprehensive Review and Detailed Analysis
by: Jay M. Lee, MD, et al.
Published: (2025-09-01)

Mapping the immunological landscape and emerging immunotherapeutic strategies in cervical cancer: a comprehensive review
by: Xinyi Zhang, et al.
Published: (2025-07-01)

Synthesis and Evaluation of [<sup>18</sup>F]AlF-NOTA-iPD-L1 as a Potential Theranostic Pair for [<sup>177</sup>Lu]Lu-DOTA-iPD-L1
by: Guillermina Ferro-Flores, et al.
Published: (2025-07-01)

Bimodal onset and pan-cancer uniformity of immune-mediated liver injury: a retrospective cohort study
by: Jiaojiao Song, et al.
Published: (2025-07-01)

Systematic literature review of real-world evidence on overall survival in cancer patients before and after the approval of anti-PD-(L)1 therapy
by: Dweeti Nayak, et al.
Published: (2025-08-01)

New horizons in B-cell lymphoma immunotherapy: From immune checkpoints to precision medicine
by: RuiXin Zheng, et al.
Published: (2025-09-01)

Long-term overall and relapse-free survival in a patient with metastatic non-small cell lung cancer treated with immunotherapy. A case report
by: G. V. Afonin, et al.
Published: (2025-01-01)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
by: Miao Wang, et al.
Published: (2021-12-01)

Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)
by: M. Yu. Fedyanin, et al.
Published: (2023-06-01)

Metabolism of tryptophan in non-small lung cancer patients with different effect of PD-1 / PD-L1 inhibitors immunotherapy
by: E. Yu. Zlatnik, et al.
Published: (2022-06-01)

The regulatory effects of PD-1/PD-L1 inhibitors on bone metabolism: opportunities and challenges in osteoporosis management
by: Jia-Wen Wang, et al.
Published: (2025-07-01)

Cryoablation combined with programmed cell death protein 1 (PD-1) inhibitors regulates myeloid-derived suppressor cells (MDSCs) through the JAK2-STAT3-S100A8/A9 axis in mice with Lewis lung carcinoma
by: Jiao Li, et al.
Published: (2025-12-01)

Exosomal PD-L1 detection in cancer predictive biomarker for response to immune checkpoint blockade therapy
by: Tetsuichi Kansha, et al.
Published: (2025-07-01)

Enhancing CAR-T Efficacy: The Role of Anti PD-1/PD-L1 Checkpoint Inhibitors in Modern Cancer Treatment
by: Rishi Kant, et al.
Published: (2025-06-01)

Immune-mediated adverse rheumatic reactions following administration of immune checkpoint inhibitors
by: I. V. Menshikova, et al.
Published: (2020-09-01)

PD-L1 as a Potential Target in Cancer Therapy (Review)
by: N. N. Andrusova, et al.
Published: (2021-02-01)

Changes in the level of immune checkpoints in patients with various forms of autoimmune thyroiditis
by: V. V. Babinsky
Published: (2024-09-01)

IRF4 Mediates Immune Evasion to Facilitate EBV Transformation
by: Ling Wang, et al.
Published: (2025-06-01)

Ligand-associated activation of vitamin D receptors and potential points of application of its effects in the morphogenesis of immune inflammation: Literature review
by: E. T. Ablyakimov, et al.
Published: (2024-07-01)

CTLA-4 and PD-1 combined blockade therapy for malignant melanoma brain metastases: mechanisms, challenges, and prospects
by: Jia-Wen Wang, et al.
Published: (2025-07-01)

Evaluation of the Effectiveness and Safety Profile of First-Line Immune Checkpoint Inhibitors Combined with Chemotherapy in Pulmonary Sarcomatoid Carcinoma
by: Du H, et al.
Published: (2025-06-01)

Activity of Negative Regulation of the PD-1/PD-L1/PD-L2 T-Cell Response System in Patients with Pneumonia and Inﬂuenza A (H1N1)
by: A. V. Malyarchikov, et al.
Published: (2021-08-01)

Gamma Knife stereotactic radiotherapy combined with tislelizumab as later-line therapy in pMMR/MSS/MSI-L metastatic colorectal cancer: a phase II trial analysis
by: Yiran Zhang, et al.
Published: (2025-06-01)

PD-L1 expression in microvascular endothelial cells predicts the efficacy and side effects of anlotinib
by: Yingfang Feng, et al.
Published: (2025-07-01)

Updated pharmacoeconomic analysis of atesolizumab efficiency compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy
by: S. K. Zyryanov, et al.
Published: (2023-11-01)

A Delayed Presentation of Immune Checkpoint Inhibitor Colitis
by: Alicia Nahhas, et al.
Published: (2025-06-01)

The Benefit of Brentuximab Vedotin and Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Single-Center Retrospective Study
by: Diana-Marina FORTOES, et al.
Published: (2025-06-01)

Galectin-9 and Tim-3 in gastric cancer: a checkpoint axis driving T cell exhaustion and Treg-mediated immunosuppression independently of anti-PD-1 blockade
by: Charlotte N. Hill, et al.
Published: (2025-07-01)

Involvement of the Programmed Death 1/Programmed Death Ligand 1 Pathway in the Immune Microenvironment of Chronic Periapical Lesions
by: Yujin Song, et al.
Published: (2025-08-01)